p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patient...
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane
About this item
Full title
Author / Creator
Vanacker, Hélène , Treilleux, Isabelle , Schiffler, Camille , Bieche, Ivan , Campone, Mario , Patsouris, Anne , Arnedos, Monica , Cottu, Paul H. , Jacquin, Jean-Philippe , Dalenc, Florence , Pinton, Antoine , Servant, Nicolas , Attignon, Valéry , Rouleau, Etienne , Morel, Alain , Legrand, François , Jimenez, Marta , Andre, Fabrice and Bachelot, Thomas
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background
To identify patients most likely to respond to everolimus, a mammalian target of rapamycin (mTOR) inhibitor, a prospective biomarker study was conducted in hormone receptor-positive endocrine-resistant metastatic breast cancer patients treated with exemestane-everolimus therapy.
Methods
Metastatic tumor biopsies were processed f...
Alternative Titles
Full title
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane
Authors, Artists and Contributors
Author / Creator
Treilleux, Isabelle
Schiffler, Camille
Bieche, Ivan
Campone, Mario
Patsouris, Anne
Arnedos, Monica
Cottu, Paul H.
Jacquin, Jean-Philippe
Dalenc, Florence
Pinton, Antoine
Servant, Nicolas
Attignon, Valéry
Rouleau, Etienne
Morel, Alain
Legrand, François
Jimenez, Marta
Andre, Fabrice
Bachelot, Thomas
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10876520
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10876520
Other Identifiers
ISSN
0007-0920,1532-1827
E-ISSN
1532-1827
DOI
10.1038/s41416-023-02549-8
